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Abstract
Background: Rapid tests (RTs) might have several advantages over standard laboratory procedures, increasing
access to diagnosis, especially among vulnerable populations and/or those living in remote areas. The aim of this
study was to evaluate the performance of RTs for the detection of hepatitis B virus surface antigen (HBsAg) in
samples from different populations/settings.
Methods: Three RTs for HBsAg detection (Vikia® HBsAg, HBsAg Teste Rápido®, and Imuno-Rápido HBsAg®) and
different biological specimens (serum, whole blood, and saliva) were evaluated. Analyses comprised a reference
panel and samples from field studies targeting suspected cases of hepatitis B virus (HBV) (G I), individuals living in
deprived areas (G II), and highly vulnerable individuals (G III). Enzyme immunoassay (EIA) was defined as the gold
standard in this study. Reproducibility, repeatability, and cross-reactivity with other infectious agents such as
dengue, immunodeficiency (HIV), and hepatitis C (HCV) viruses and T. pallidum were determined.
Results: For the reference panel, the sensitivity and specificity of all HBsAg RTs were higher than 93.00 %. G I
presented the highest kappa values for all rapid assays using sera samples. When using serum, the sensitivity values
were higher than 93.40 for G I, 60.00 % for G II and 66.77 % for G III, and the specificity values were higher than 99.50
for GI, 97.20 for G II and 99.10 % for G III for all tests. For whole blood samples & the Vikia® HBsAg assay, the best
performance was achieved for GIII (k = 79.75 %). For saliva samples, the Imuno-Rápido HBsAg® assay showed the
highest concordance values with EIA for G I (40.68 %) and G II (32.20 %). The reproducibility and repeatability of all RTs
for serum and saliva were excellent, and the concordance between HBsAg EIAs and RTs using samples reactive
with other infectious agents varied from 70.10 % to 100.00 %.
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Conclusions: The overall performance of RTs for HBsAg in serum was high/moderately high for all groups, thereby
promoting increased access to HBV diagnosis among vulnerable populations as well as samples from individuals in
emergency settings or remote areas. Rapid tests for HBsAg using whole blood could be used in prevalence studies,
though these assays should not be used for saliva samples.
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Background
Exposure to hepatitis B virus (HBV) may result in acute
and chronic infections. Two billion individuals are esti-
mated to have had contact with the virus and 240 million
to be chronic carriers of HBV. Every year, approximately
600 thousand people die due to late complications of
HBV infection [1].
Standard HBV diagnosis consists of the use of enzyme
immunoassays (EIAs) and electrochemiluminescence
(ECLIA) with serum or plasma samples [2]. However,
these assays have limitations that may compromise their
routine use in low- and middle-income countries: they
require trained personnel as well as the availability of all
necessary infrastructures. As an alternative, rapid tests
(RTs) may have several advantages over standard proce-
dures because they are easy to perform and can provide
conclusive results within a few minutes. Additionally,
these tests may be performed on a case-by-case basis
and do not require laboratory infrastructure. Moreover,
only minimal training is required to perform RTs [3–5].
Rapid tests for detection of the surface antigen of the
hepatitis B virus (HBsAg) utilize a lateral flow device.
Different approaches can be used in lateral flow assays,
but in general, the patient’s sample is poured over a
membrane containing two areas: the first contains anti-
bodies against HBsAg (anti-HBs) for detection; and the
second, the control area, contains a set of reagents that
represents the quality control of the conjugate [4].
HBsAg RTs have been used for HBV clinical diagnosis
and in serosurveys in different settings and countries
[4–7]. In Brazil, although rapid tests for human im-
munodeficiency virus (HIV) and hepatitis C virus (HCV)
have been widely used, as recommended by the Brazilian
Ministry of Health (BMoH) [8, 9], no standard algorithm
or guideline is yet available for HBV RTs. Before the
implementation of rapid testing for HBV diagnosis,
key parameters such as their sensitivity, specificity, cross-
reactivity, reproducibility, and repetitively should be thor-
oughly evaluated.
The determination of the accuracy of a rapid test com-
pared to a “gold standard” diagnostic procedure, such as
ELISA, is key to minimizing false positive or negative
results, thus increasing access to accurate diagnosis in
remote areas and/or emergency settings. The aim of this
study was to evaluate the performance of three rapid
tests for HBsAg detection using three different types of
fluid from individuals in different populations/settings.
Methods
Study population
No comprehensive population-based serosurvey in Brazil
on HBV has been implemented to date. Local/focal stud-
ies have highlighted infection rates in different segments
of the general population, and different at-risk groups
are deeply heterogeneous. A comprehensive panel of sera
from different key groups was established by the authors.
Although based on convenience samples, it intentionally
targeted as many populations and settings as possible,
from all over the country.
The reference panel comprised serum samples obtained
from 393 individuals recruited between 2010 and 2012 at
Fiocruz Viral Hepatitis Ambulatory (Oswaldo Cruz Insti-
tute, Rio de Janeiro, Brazil), a Brazilian Referral center for
the diagnosis of viral hepatitis (types A, B, C, D and E).
The inclusion criteria for this group were acute, chronic
or suspected cases of hepatitis B infections, age of more
than 18 years and signed informed consent. Samples from
individuals under follow-up at the Fiocruz outpatient
clinic were tested for HBsAg using two ELISA kits
(HBsAg, Radim, Pomezia, Italy and ETI-MAK-4, Diasorin,
Italy) and three rapid tests (Vikia® HBsAg, Biomérieux,
France; HBsAg Teste Rápido®, Doles, Brazil, and Imuno-
Rápido HBsAg®, Wama, Brazil).
A field study was composed of three groups (I-III),
with each participant providing serum, whole blood and/
or saliva. The serum samples were tested for HBsAg
using one ELISA kit (ETI-MAK-4, Diasorin, Italy), and
all biological samples were assayed for all RTs evaluated.
Group I (G I) comprised 371 individuals referred
to Fiocruz Viral Hepatitis Ambulatory (Oswaldo Cruz
Institute, Rio de Janeiro) from 2009 to 2013. Inclu-
sion criteria were attendance at Fiocruz Viral Hepatitis
Ambulatory, residing in underserved and impover-
ished areas in Rio de Janeiro City (capital of Rio de
Janeiro State) and a suspected case of viral hepatitis
infection. This group was considered the high-risk
group.
Group II (G II) comprised 881 individuals living in
three (of the five) Brazilian macro-regions (Southeast,
North and Midwest) and belonging to the general
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population, among which HBV prevalence has been low
in recent years. None of these individuals were recruited
in viral hepatitis ambulatory care settings, and this group
was considered to be a low risk for HBV. These samples
were obtained from individuals living in Rio de Janeiro
State (Petrópolis and Macaé cities), Tocantis State
(Tocantinópolis city), and Mato Grosso do Sul State (the
Pantanal region) in 2009–2013 and who agreed to be
tested within the context of public campaigns aiming to
increase viral hepatitis diagnosis and the prompt referral
of infected patients for treatment and care. The individ-
uals from Mato Grosso do Sul State lived in communi-
ties of the Pantanal region, up to 385 km far from
Campo Grande City (Mato Grosso do Sul State),
whereas other individuals lived up to 217 km far (by
river transportation) from the city of Corumbá (Mato
Grosso do Sul State). The individuals from Tocantins
State lived in rural communities from Tocantinópolis,
30 km far away from the urban area of the city. Such in-
dividuals belong to socially isolated populations living in
deprived, underserved communities.
The individuals from Rio de Janeiro State were
employees from a private hospital located in Petrópolis
city who belonged to the middle-class as well as individ-
uals living in underprivileged communities of Macaé
city. Petrópolis city is located in a mountain region, and
Macaé city is situated in the northern region of Rio de
Janeiro State.
Our aim in this study was to assess as many individ-
uals as possible from remote areas and/or deprived com-
munities, as well as a small subgroup of people from the
middle-class stratum. This subgroup falls short of a
population-based repository, but deliberate efforts were
made to establish a pool as diverse as possible, focusing
on underserved populations that could benefit the most
from extended testing strategies.
Finally, Group III (G III) was composed of 251
vulnerable individuals, including 158 beauticians and
93 heavy users of crack cocaine from Rio de Janeiro
State.
All study participants and/or their legal guardians
consented and signed informed consent forms prior to
enrollment. Ethical approval for the study was issued by
the Oswaldo Cruz Foundation Ethics Committee. La-
boratory results were promptly returned to the patients’
physicians.
Sample collection
Whole blood and serum samples were collected by
venipuncture using vacutainer tubes, with (BD Vacutainer®
containing the anticoagulant EDTA) and without (BD SST
II Advance®) additives, respectively. Saliva samples were
collected using commercial collection devices (Salivette®;
Sarstedt, Germany) and were mixed with 1 ml of transport
buffer. Oral fluid samples were centrifuged (1,400 × g for
10 min) and stored at −20 °C until assayed, as detailed
elsewhere [10]. For the reference panel, only serum sam-
ples were assayed, whereas serum, whole blood and saliva
the field studies were analyzed.
HBsAg and HBV detection
Serum samples from the reference panel were tested for
HBsAg markers using two commercial EIAs (HBsAg,
Radim, Pomezia, Italy and ETI-MAK-4, Diasorin, Italy)
following the manufacturers’ instructions. Only samples
with concordant results defined by both assays were in-
cluded in the study. Serum samples from the field study
were assayed for HBsAg detection using a commercial
EIA (HBsAg, Radim, Pomezia, Italy). All HBsAg-reactive
samples in the EIA were retested in duplicate. All serum
samples were assayed for total antibodies directed
against the total core antigen (anti-HBc total) as well as
anti-HBs using EIAs (Diasorin, Italy). Serum samples
were also assayed for anti-HBc IgM, HBV “e” antigen
(HBeAg) and antibodies against HBeAg (anti-HBe) using
commercial EIAs and ECLIAs (Diasorin, Italy) when suf-
ficient sample volume was available.
Rapid test evaluation
Three HBsAg rapid tests were evaluated: Vikia® HBsAg
(Biomerieux, France), HBsAg Teste Rápido® (Doles,
Brazil), and Imuno-Rápido HBsAg® (Wama, Brazil). All
the RTs are approved by the Brazilian National Health
Surveillance Agency (ANVISA), which is responsible for
the regulation, control and supervision of products
and services that involve risk to public health. Vikia®
HBsAg has CE IVD approval but does not have FDA
approval or WHO registration. Imuno-Rápido HBsAg®
does not have FDA approval or WHO registration;
such information is not available for HBsAg Teste
Rápido®.
All three tests are qualitative tests based on immuno-
chromatographic techniques for lateral association of
monoclonal and polyclonal antibodies specific for
HBsAg. The Vikia® HBsAg allows the detection of the
main ad and ay subtypes in serum, plasma and whole
blood by adding 75 μl of each sample to the test plat-
form. Capillary blood by fingerstick can also be used in
this test.
According to the manufacturers’ instructions, the ana-
lytical sensitivity of the RTs is less than or equal to 2 IU/
ml for Vikia® HBsAg and from 10 IU/ml for HBsAg Teste
Rápido® and Imuno-Rápido HBsAg®.
Readings were available within 15 min (though for
negative samples, it was necessary to wait up to 30 min
to confirm the result). The Imuno-rápido HBsAg® and
HBsAg teste rápido® tests allow the detection of HBsAg
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in serum samples, and both assays use 100 microliters of
sample. The results can be assessed within 20 min.
All procedures for rapid tests were performed accord-
ing to the manufacturers’ recommendations, except for
the saliva samples, for which twofold increases in sample
volume (i.e., 75 μl→ 150 μl and 100 μl→ 200 μl) were
adopted to increase the sensitivity of HBsAg detection.
The manufacturers’ recommendations do not include
the analysis of saliva samples. However, previous at-
tempts made by our research group with regard to hepa-
titis C [11] were successful and motivated the current
attempt. In the present study, we extended saliva ana-
lyses by incorporating HBsAg detection. Serum and
saliva were assayed for all HBsAg RTs, and whole blood
samples were evaluated using the Vikia® HBsAg test
because it is the only test specifically designed for the
latter.
Reproducibility and repeatability
To evaluate the reproducibility and repeatability of
HBsAg rapid tests, four samples (2 serum and 2 saliva
samples) were tested in eleven replicates, each by two
different operators, for two consecutive days. One HBsAg-
reactive and another HBsAg-non-reactive serum sample
by EIA were included. HBV-negative individuals donated
saliva samples. These saliva samples were then diluted
(1:1) with an HBV-reactive serum sample.
The HBsAg rapid testing procedures were similar to
the procedures described above for serum and saliva.
kappa statistics were used to cross-compare the results
of rapid tests and EIA.
Cross-reactivity studies
Serum samples reactive for other infectious agents were
included in the analysis to assess the cross-reactivity of
the HBsAg rapid tests. Twenty serum samples reactive
for dengue virus (five for each of the co-circulating sero-
types: DENV-1, DENV-2, DENV-3 and DENV-4), 69
HIV-reactive serum samples, 49 Treponema pallidum-
reactive serum samples, and 137 HCV-reactive samples
were included. HBsAg was assayed using commercial
EIA (HBsAg One, RADIM) and HBsAg rapid tests
(Vikia® HBsAg; HBsAg Teste Rápido®, and Imuno-
Rápido HBsAg®).
Data analysis
The data analysis comprised samples with well-defined
serology. Indeterminate samples detected by EIA were
excluded. Socio-demographic, epidemiological, clinical,
EIA and rapid test results were entered into an Access®
database. Statistical analyses were performed using SPSS
20.0 for Windows (SPSS Inc., USA). Parameters associated
with test performance were evaluated using GraphPad
InStat Programs, version 3.01 (GraphPad Software, San
Diego, USA) and MedCalc, version 9.2.1.0 (MedCalc
Software, Mari-akerke, Belgium).
The RT results were cross-compared with the EIA
results, which was defined for the sake of this study as
the gold standard. Analytic categories were defined as
follows: true positive results (TP – positive in both
tests), true negative results (TN – negative in both tests),
false positive results (FP – positive in RT and negative in
commercial EIA), false negative results (FN – negative
in RT and positive in commercial EIA).
The clinical sensitivity (Cs), specificity (S), positive
predictive value (PPV), and negative predictive value
(NPV) for each rapid test were evaluated, and their re-
spective 95 % confidence intervals (95 % CI) were calcu-
lated. Contingency tables and respective statistics were
used to cross-compare findings from different testing
procedures and populations/settings.
Concordance between the panel’s results and the
results from rapid tests was assessed by kappa statistics
[12]. P-values (two-tailed) <0.05 were considered statisti-
cally significant.
Results
HBsAg rapid test performance using reference panels
The reference panel was composed of 393 individuals,
103 of which were HBsAg reactive (sera), whereas 290
samples did not show HBsAg according to EIAs. The
mean age (± standard deviation) of the patients was
40.32 years (±14.78), and most were female (61.24 %).
HBsAg was detected in 101, 98 and 96 of the samples,
with sensitivities of 98.06, 95.15 and 93.20 % by Vikia®
HBsAg, Imuno-Rápido HBsAg® and HBsAg Teste Rápido®,
respectively (Table 1).
According to the three RT assays, HBsAg false nega-
tive serum samples had a low optical density/cut-off
value ratio (OD/CO) by EIA when compared to HBsAg
true positive samples (concise information about the ana-
lytical detection limits is available in Additional file 1:
Web Appendix 1).
Most of the HBsAg-reactive samples also presented
anti-HBc total, whereas anti-HBc and anti-HBs were not
detected in most of the HBsAg-non-reactive samples, in-
dependent of the group studied (21.60 to 65.70 %). In
addition, anti-HBc IgM, HBeAg, anti-HBe were most
frequently detected in the reference panel and group I
(the serological characteristics of HBV markers is avail-
able in Additional file 1: Web Appendix 2).
HBsAg rapid test performance using field samples
Overall, 3,273 biological samples were collected in the
different field studies, and 1,503 serum, 1,268 whole
blood and 502 saliva samples were included in the ana-
lyses. The mean age of the individuals was 32.63
(±18:43) years, 34.89 (±12.95) years and 34.06 (±16:15)
Cruz et al. BMC Infectious Diseases  (2015) 15:548 Page 4 of 10
Table 1 Accuracy metrics (point estimates and 95%CIs) of three rapid tests compared to results of HBsAg One® and ETI-MAK-4®, enzyme immunoassays
Manufacturer TP FN TN FP Sensitivity Specificity PPV NPV K (CI%)
HBsAg non-reactive/HBsAg reactive (n = 393)
Vikia HBsAg® 101 2 290 0 98.06 % (93.16–99.76) 100.00 % (98.74–100.00) 100.00 % (96.42–100.00) 99.32 % (97.54–99.92) 98.68 % (96.85–100.00)
Imuno-Rápido HBsAg® 98 5 287 3 95.15 % (89.03–98.40) 98.97 % (97.01–99.79) 97.03 (91.58–99.38) 98.29 % (96.05–99.44) 94.7 % (91.07–98.33)
HBsAg teste rápido® 96 7 287 3 93.20 % (86.51–97.22) 98.97 % (97.01–99.79) 96.97 % (91.39–99.37) 97.62 % (95.16–99.04) 93.34 % (89.26–97.42)















years for those donating serum, whole blood and saliva,
respectively. Most individuals were women (51.93 % for
serum, 55.19 % for whole blood, and 52.93 % for saliva).
The number of serum, whole blood and saliva samples
from the different groups can be summarized as follows:
G I - 371, 108 and 185 individuals; G II - 881, 767 and
160 individuals; G III - 251, 393 and 157 individuals, re-
spectively. Overall (all groups and serum samples), Vikia
HBsAg® presented the highest kappa value (96.08 %),
followed by HBsAg teste rápido® (88.41 %) and Imuno-
rápido HBsAg® (87.62 %). The specificities of all RTs
were higher than 97 %, and Vikia HBsAg presented the
highest sensitivity (Table 2).
For serum samples from G I, the sensitivity was 93.41,
94.01, and 95.81 % and specificity 99.51, 99.51, and
100.00 % using HBsAg teste rápido®, Imuno-rápido
HBsAg® and Vikia HBsAg®, respectively. For samples
from G II, sensitivity was 60.00 % for all tests, and speci-
ficity was 97.83, 97.26, and 99.89 % for HBsAg teste
rápido®, Imuno-rápido HBsAg® and Vikia HBsAg®, re-
spectively. With respect to G III, sensitivity was 66.77 %
for all tests, and specificity was 99.18 , 99.59, and
100.00 % for HBsAg teste rápido®, Imuno-rápido HBsAg®
and Vikia HBsAg®, respectively.
As observed in the reference panel, HBsAg false nega-
tive samples, as defined by RTs, presented low values of
OD/CO by EIA compared to true HBsAg-positive sam-
ples (Additional file 1 available in Web Appendix 1).
The Vikia HBsAg® test performed using whole blood
samples presented the highest kappa value for G III
(79.75 %), followed by G I (72.7 %). Concordance was
not determined among the G II samples because the test
could not detect true positives. Immuno-Rápido HBsAg®
demonstrated the highest kappa value with EIA for G I
(40.68 %) saliva samples, followed by G III (32.20 %). For
G III samples, none of the available RTs could detect
true HBsAg-positive samples; thus, a concordance value
could not be calculated (Table 3).
Reproducibility and repeatability
Reproducibility and repeatability analyses comprised 528
tests (264 serum and 264 saliva samples). The HBsAg
teste rápido®, Immuno-Rápido HBsAg® and Vikia HBsAg®
assays exhibited a 100.00 % kappa value for the EIA results
for all samples (i.e., serum and saliva samples HBsAg re-
active/non-reactive).
Cross-reactivity with other infectious agents
HIV-, dengue virus-, HCV- and T. pallidum-reactive
samples were evaluated using HBsAg rapid tests and
EIA. HBsAg-reactive results were found among eight
HCV samples, nine T. pallidum samples, and 15 HIV
samples using EIA. In contrast, no HBsAg-reactive sam-
ple was found among the DENV samples.
The kappa statistic for EIA and RTs for HBsAg detec-
tion varied from 76.60 % to 85.10 % for T. pallidum,
70.10 % to 81.10 % for HIV, 78.80 % to 86.70 % for HCV
and 100 % for dengue for all manufacturers. False nega-
tive results were found for all manufacturers for T. palli-
dum, HIV and HCV, and false positive results were
found in one HIV-reactive sample (using HBsAg teste
rápido®) and two HCV-reactive samples (one by HBsAg
teste rápido® and the other by Immuno-Rápido HBsAg®)
(Table 4).
Discussion
The present study demonstrates the usefulness of
HBsAg rapid tests in both the lab and the field. All rapid
tests detected HBsAg among serum samples from a ref-
erence panel, with high sensitivity and specificity within
contexts of high background prevalence. However, sensi-
tivity was found to be poor when the background preva-
lence was low. In the field study, HBsAg rapid tests
demonstrated a higher than 96.00 % specificity among
serum samples, regardless of the manufacturer and the
group under study, demonstrating the ability of these as-
says to detect HBsAg true negative samples [5, 12–15).
The performance of RTs could be influenced by the anti-
gen concentration because false negative samples had
low average values of OD/CO compared to true positive
samples, in agreement with previous studies [4, 14].
In the present study, the presence of HBV markers,
such as anti-HBc or anti-HBs, did not appear to influ-
ence the HBsAg RT results. However, it was not possible
to evaluate all the samples for HBeAg, anti-HBe and/or
anti-HBc IgM due to low sample volumes. Thus, it was
not possible to evaluate the influence of these markers
on the performance of HBsAg RT performance.
The Vikia HBsAg® test presented the best performance
in both the laboratory and field for serum samples, and
the highest concordance was observed among G I pa-
tients. Such optimal performance may be secondary to
the high HBsAg prevalence in this group, as observed by
Lien et al. [13] using RTs from other manufacturers. In
Brazil, confirmed HBV cases from 1999 to 2011 (120.343)
were most reported in the southeast region (36.30 %),
where Rio de Janeiro is located (16).
Low HBsAg prevalence could influence the perform-
ance of rapid tests, as found for the G II and G III sam-
ples. In Brazil, the HBsAg prevalence varies from 0.63 %
in the northern region to 0.31 % in both the southeastern
and midwestern regions [16]. Previous studies conducted
among beauticians and crack users showed a lower HBsAg
prevalence of 0 % to 6.2 % in Rio de Janeiro [17, 18].
However, in the present study the prevalence in these
groups was 2.3 %, corroborating the a priori assump-
tion these groups are particularly vulnerable to HBV
infection.
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Table 2 Accuracy metrics (point estimates and 95%CIs) of three rapid tests compared to results obtained by enzyme immunoassay ETI-MAK-4® in serum samples according to
the characteristics of the study population
Profile/Manufacturer (n) TP FN TN FP Sensitivity Specificity PPV NPV K
Group I
Vikia HBsAg ®(371) 160 7 204 0 95.81 % (91.54–98.30) 100.00 % (98.21–100.00) 100.00 % (97.72–100.00) 96.68 % (93.30–98.65) 96.17 % (93.36–98,98)
Imuno-rápido HBsAg® (371) 157 10 203 1 94.01 % (89.27–97.09) 99.51 % (97.30–99.99) 99.37 % (96.53–99.98) 95.31 % (91.53–97.72) 93.98 % (90.48–97.48)
HBsAg Teste rápido® (371) 156 11 203 1 93.41 % (88.53–96.67) 99.51 % (97.30–99.99) 99.36 % (96.51–99.98) 94.86 % (90.99–97.41) 93.43 % (89.77–97.09)
Group II
Vikia HBsAg ®(881) 3 2 875 1 60.00 % (14.67–94.73) 99.89 % (99.37–100.00) 75.00 % (19.42–99.37) 99.77 % (99.18–99.97) 66.50 % (28.65–100.00)
Imuno-rápido HBsAg® (881) 3 2 852 24 60.00 % (14.67–94.73) 97.26 % (95.94–98.24) 11.11 % (23.55–29.18) 99.77 % (99.16–99,97) 17.96 % (0.00–49.02)
HBsAg Teste rápido® (881) 3 2 857 19 60.00 % (14.67–94.73) 97.83 % (96.63–98.69) 13.64 % (29.04–34.94) 99.77 % (99,16–99.97) 21.50 % (0.00–54.67)
Group III
Vikia HBsAg ®(251) 4 2 245 0 66.67 % (22.27–95.67) 100.00 % (98.51–100.00) 100.00 % (39.76–100.00) 99.19 % (97.11–99.90) 79.61 % (51.46–100.00)
Imuno-rápido HBsAg® (251) 4 2 244 1 66.67 % (22.27–95.67) 99.59 % (97.75–99.99) 80.00 % (28.35–99.49) 99.19 % (97.11–99.90) 72.12 % (40.76–100.00)
HBsAg Teste rápido® (251) 4 2 243 2 66.67 % (22.27–95.67) 99.18 % (97.08–99.90) 66.67 % (22.27–95.67) 99.19 % (97.11–99.90) 65.85 % (32.65–99.05)
Overall
Vikia HBsAg ® (1503) 167 11 1324 1 93.82 % (89.21–96.87) 99.92 % (99.58–100.00) 99.40 % (96.73–99.98) 99.18 % (98.53–99.59) 96.08 % (93.87–98.29)
Imuno-rápido HBsAg® (1503) 164 14 1299 26 92.13 % (87.14–95.63) 98.04 % (97.14–98.71) 86.32 % (80.57–90.86) 98.93 % (98.21–99.42) 87.62 % (83.83–91.41)
HBsAg Teste rápido® (1503) 163 15 1303 22 91.57 % (86.50–95.21) 98.34 % (97.49–98.96) 88.11 % (82.57–92.39) 98.86 % (98.13–99.36) 88.41 % (84.72–92.1)














The best performance of the Vikia HBsAg® test in
whole blood samples was observed in the G III samples,
favoring the applicability of this rapid test to vulnerable
individuals. Nonetheless, the kappa value was relatively
low (72.73 %) compared to a previous study conducted
in France (96.98 %) [4]. The observed difference may be
secondary to different blood collection procedures:
blood was obtained by venipuncture in tubes without
anticoagulant in the previous study [4] yet by venipuncture
in tubes with anticoagulant in the present study.
The best performance for saliva samples was achieved
using the Immuno-Rápido HBsAg® assay in the G I and
II samples. However, a high number of false negative re-
sults were observed for the tests from all manufacturers,
regardless of the group under study, which is most likely
secondary to the low concentration of HBsAg in saliva
samples [19]. In addition, HBsAg rapid tests were not
originally developed for saliva samples, which may also
explain the low concordance with EIA results.
Accordingly, our findings must be viewed as a warning
against the use of these procedures for HBsAg detection
in saliva samples. The previous promising findings re-
specting hepatitis C testing were, unfortunately, not
observed for HBsAg.
In the present study, the volume of saliva sample was
increased in all rapid tests to improve the sensitivity of
the assay, but this procedure could not be translated
into concrete benefits. Additional modifications, such
as a longer incubation period, may be pursued by future
studies.
The HBsAg rapid tests demonstrated excellent re-
peatability and reproducibility in serum and artificially
contaminated saliva samples, demonstrating the good per-
formance of these assays under laboratory conditions.
Although two meta-analysis studies showed high pooled
accuracy for RTs for HBsAg [20, 21], Khuroo et al. [21]
also observed wide variation in sensitivity among individ-
ual tests (43.5 % to 99.8 %), which could be due to the de-
sign of the studies or population characteristics because
the performance of RTs are better in developed than in
developing countries. In the present study, a wide variation
of sensitivity of RTs for HBsAg was observed according to
the group studied (60.00 % to 95.81 %), demonstrating the
importance of evaluating RTs among specific populations
before implementation at a large scale.
Regarding cross-reactivity, the best results using serum
samples were found among reactive dengue samples,
most likely due to the absence of HBsAg-reactive samples
Table 3 Kappa statistics and positive and negative samples detected by rapid tests using saliva (3) and whole blood (1) samples
compared to results obtained using respective serum samples by enzyme immunoassay ETI-MAK-4®, according to the characteristics
of the population under analysis
Profile/Manufactory – Biological specimen TP FN TN FP K
Group I
Vikia HBsAg® - SALIVA 6 76 101 2 5.92 % (0.00–21.8)
Imuno-Rápido HBsA® - SALIVA 33 49 101 2 40.68 % (26.82–54.54)
Teste rápido HBsAg®- SALIVA 2 80 101 2 0.55 % (0.00–16.61)
Vikia HBsAg® - WHOLE BLOOD 18 10 80 0 72.73 % (56.63–88.83)
Group II
Vikia HBsAg® - SALIVA 0 2 153 5 a
Imuno-Rápido HBsA® - SALIVA 1 1 155 3 32.2 % (0.00– 97.8)
Teste rápido HBsAg® - SALIVA 0 2 158 0 a
Vikia HBsAg® - WHOLE BLOOD 0 3 763 1 a
Group III
Vikia HBsAg® - SALIVA 0 4 153 0 a
Imuno-Rápido HBsA® - SALIVA 0 4 149 4 a
Teste rápido HBsAg® - SALIVA 0 4 150 3 a
Vikia HBsAg® - WHOLE BLOOD 4 2 387 0 79.75 % (51.76–100.00)
Overall
Vikia HBsAg® - SALIVA 6 82 407 7 7.72 % (0,00–25,11)
Imuno-Rápido HBsA® - SALIVA 34 54 405 9 45.65 % (33.1–58.2)
Teste rápido HBsAg® - SALIVA 2 86 409 5 1.67 % (0.00–19.95)
Vikia HBsAg® - WHOLE BLOOD 22 15 1230 1 72.72 % (59.44–86.00)
Legend: TP True positive, FN False negative, TN True negative, FP False positive, k kappa statistics, n number of observations (biological samples), CI confidence interval
anot amenable to calculation
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and/or the low number of dengue samples under analysis
(i.e., due to beta error). Regardless, for T. pallidum-, HIV-
and HCV-reactive samples, false negative and positive
HBsAg results were observed for all RTs. However, the
poorest performance was observed among HIV-reactive
samples. This is of concern because under real life
conditions, a non-negligible fraction of patients may
be co-infected by the two viruses, which may yield
confusing results and inconclusive clinical interpretations.
The Vikia HBsAg® and HBsAg teste rápido® tests
showed better kappa values for HIV- and HCV-reactive
samples, respectively, and both Vikia HBsAg® and
HBsAg teste rápido® showed better kappa values for T.
pallidum-reactive samples. These results suggest that
both assays may have good performance with samples
reactive for other infections. Other HBsAg RTs pre-
sented good performance among HIV-reactive samples
[6, 7]. In addition, a meta-analysis demonstrated that
co-infections (for example HIV, HCV, tuberculosis)
did not influence the diagnostic accuracy of HBsAg
RTs, which could be helpful for the adoption of these
assays in endemic areas where these co-infections are
highly prevalent [21].
This study presents some limitations, such as the
absence of HBsAg neutralization, HBV DNA testing or
HBsAg concentration due to low sample volume. However,
reactive HBsAg samples were retested in duplicate to con-
firm the HBsAg results.
Conclusion
In conclusion, the present study showed moderate to high
concordance of HBsAg rapid tests using serum samples
from different populations/settings. These findings could
be useful for HBV diagnosis among individuals who are
highly vulnerable to HBV infection as well as those
recruited from emergency settings or remote areas. In
addition, saliva samples should not be used for HBsAg
detection with the assays evaluated in the present study.
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